The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
Actins
/ metabolism
Aged
Biomarkers, Tumor
/ metabolism
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ metabolism
Neoplasm Staging
Platelet Endothelial Cell Adhesion Molecule-1
/ metabolism
Prospective Studies
Prostatectomy
Prostatic Neoplasms
/ metabolism
Receptors, Androgen
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Tissue Array Analysis
/ methods
Tumor Microenvironment
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
09
2020
accepted:
15
12
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
20
3
2021
Statut:
epublish
Résumé
The tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-prostatectomy. Tissue micro-arrays (TMA) were composed with both prostate non-tumour (PNT) and PCa tissue and subsequently processed for immunohistochemistry (IHC). The IHC panel included markers for cancer activated fibroblasts (CAFs), blood vessels and steroid hormone receptors ((SHR): androgen receptor (AR), progesterone receptor (PR) and estrogen receptor (ER)). Stained slides were digitalised, selectively annotated and analysed for percentage of marker expression with standardized and validated image analysis algorithms. A univariable analysis identified several TME markers with significant impact on CR: expression of CD31 (vascular marker) in PNT stroma, expression of alpha smooth muscle actin (αSMA) in PCa stroma, and PR expression ratio between PCa stroma and PNT stroma. A multivariable model, which included CD31 expression (vascular marker) in PNT stroma and PR expression ratio between PCa stroma and PNT stroma, could significantly stratify patients for CLR, with the identification of a low risk and high-risk subgroup. If validated and confirmed in an independent prospective series, this subgroup might have clinical potential for PCa patient stratification.
Identifiants
pubmed: 33370412
doi: 10.1371/journal.pone.0244663
pii: PONE-D-20-28259
pmc: PMC7769484
doi:
Substances chimiques
ACTA2 protein, human
0
AR protein, human
0
Actins
0
Biomarkers, Tumor
0
PECAM1 protein, human
0
Platelet Endothelial Cell Adhesion Molecule-1
0
Receptors, Androgen
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244663Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Int J Urol. 2015 Sep;22(9):806-15
pubmed: 26153072
Prostate. 2015 Jul 1;75(10):1043-50
pubmed: 25833156
J Clin Oncol. 2015 Nov 20;33(33):3968-71
pubmed: 26392104
Sci Rep. 2017 Feb 24;7:43378
pubmed: 28233816
Am J Pathol. 2011 Jan;178(1):79-87
pubmed: 21224046
Front Oncol. 2018 Aug 23;8:315
pubmed: 30191140
PLoS One. 2013 Jun 24;8(6):e66855
pubmed: 23826159
MLO Med Lab Obs. 2015 Dec;47(12):20-1
pubmed: 26742266
Front Oncol. 2019 Jun 26;9:539
pubmed: 31316912
World J Urol. 2010 Dec;28(6):687-92
pubmed: 19714336
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2001 Jan 15;61(2):423-7
pubmed: 11212224
Hum Pathol. 2007 Nov;38(11):1611-20
pubmed: 17868773
EMBO Mol Med. 2012 Aug;4(8):791-807
pubmed: 22745041
Clin Exp Metastasis. 2019 Apr;36(2):71-86
pubmed: 30847799
Sci Rep. 2017 Feb 21;7:42964
pubmed: 28220842
Endocr Relat Cancer. 2012 Oct 30;19(6):R187-204
pubmed: 22930558
Urology. 1999 Mar;53(3):542-7
pubmed: 10096381
Oncotarget. 2015 Jun 30;6(18):16135-50
pubmed: 25965833
Prostate. 2009 Jun 1;69(8):799-809
pubmed: 19189305
Cancer Lett. 2016 Sep 28;380(1):340-8
pubmed: 26828013
Sci Rep. 2018 Sep 25;8(1):14326
pubmed: 30254333
Med Image Anal. 2017 Jan;35:489-502
pubmed: 27614792
Prostate. 2015 Jan;75(1):84-91
pubmed: 25307287
Sci Rep. 2018 Jul 27;8(1):11358
pubmed: 30054508
Diagnostics (Basel). 2018 Jul 27;8(3):
pubmed: 30060509
PLoS One. 2016 Sep 01;11(9):e0161496
pubmed: 27583442
Br J Cancer. 2012 Mar 13;106(6):1095-9
pubmed: 22361632
PLoS One. 2015 Feb 27;10(2):e0116691
pubmed: 25723513
Eur Urol. 2018 Apr;73(4):524-532
pubmed: 28330676
PLoS One. 2014 Mar 24;9(3):e92714
pubmed: 24664419
Am J Clin Pathol. 2000 Apr;113(4):555-62
pubmed: 10761458
Proteomics. 2009 Oct;9(19):4478-94
pubmed: 19670370
Cancer Immunol Res. 2015 Sep;3(9):1017-29
pubmed: 26014097
Cell Cycle. 2009 Aug;8(15):2420-4
pubmed: 19556867
Med Image Anal. 2018 Oct;49:35-45
pubmed: 30081241
Am J Transl Res. 2014 Jan 15;6(2):140-6
pubmed: 24489993
Am J Clin Pathol. 2007 Apr;127(4):572-9
pubmed: 17369132
Front Endocrinol (Lausanne). 2015 Jan 19;5:225
pubmed: 25646090
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920
pubmed: 29977347
Prostate. 2007 Jan 1;67(1):32-40
pubmed: 16998819
Scand J Urol Nephrol. 2010 Nov;44(5):284-90
pubmed: 20459359
Cancer. 1997 Feb 15;79(4):772-9
pubmed: 9024715
Eur Urol. 2014 Sep;66(3):550-60
pubmed: 24836057
Lancet Oncol. 2014 Dec;15(13):1521-1532
pubmed: 25456371
Med Oncol. 2013;30(3):674
pubmed: 23925662
Cancers (Basel). 2017 Jan 22;9(1):
pubmed: 28117763
PLoS One. 2016 Oct 20;11(10):e0164016
pubmed: 27764093